Skip to content
The Nexus
HEALTHJul 1 · 08:30 UTCSTAT NEWSAdam Feuerstein

STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watch

STAT’s biotech scorecard for Q3 highlights key events for Amylyx Pharmaceuticals and Biogen. Amylyx will report Phase 3 results for avexitide in post-bariatric hypoglycemia, while Biogen will present detailed data from a mid-stage Alzheimer’s trial for diranersen on July 14.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Amylyx PharmaceuticalsorganizationBiogenorganizationavexitidetopicpost-bariatric hypoglycemiatopicdiranersentopicAlzheimer’s diseasetopictautopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting